Hematology

Blood disease treatments including therapies for hemophilia, sickle cell disease, and myelodysplastic syndromes.

Companies

Pipeline Drugs

622

Key People

645

Hematology Pipeline (622 drugs)

Commercial: 90Phase 3: 55Preclinical: 53Approved: 51Pre-clinical: 47Phase 1: 31Phase 2: 30Marketed: 29Phase 1/2: 29Discovery: 20Research: 14Phase III: 11Development: 7Service: 6Not specified: 6Market: 5ANDA Pending: 5IND-Enabling: 4Phase 2/3: 4Tool/Platform Development: 4Phase I/II: 4Under Development: 3Phase 1b: 3Clinical: 3commercial: 3Launched: 2BLA Submitted: 2Phase 2/Phase 3: 2Pre-market: 2Research Use Only: 2Phase not specified: 2Clinical-stage: 2Commercial Expansion: 2Phase 1b/2a: 2Phase I: 2Phase 3 (inferred from ASH presentation): 2Development/Commercial: 2Feasibility: 2Pre-clinical/Research: 2Phase II: 2Approved / Phase 3: 2ANDA Approved: 2Phase 2b: 2Various (Partner-led): 2Clinical Trials: 2Phase 3-ready: 2Not Disclosed: 1Development & Expansion: 1Assay Menu Expansion: 1Integrated Solution: 1Solution: 1Limited Launch: 1R&D / Integration: 1Commercial (Distribution): 1Phase 2a: 1Platform/Service: 1Service/Diagnostic: 1Commercial Service: 1Phase 1/Window-of-Opportunity: 1Commercial & Development: 1Commercial & Expansion: 1Development / Early Commercial: 1Planned: 1Commercial Launch: 1Commercial (ex-US); FDA Breakthrough Designation (US): 1Commercial (ex-US): 1Expanded Access: 1Clinical Trial: 1Development & Validation: 1Service Offering: 1Pre-NDA: 1Approved (CE Mark): 1Phase 3 / Registration: 1Commercial / Line Extension: 1Early Commercial/Clinical: 1Pre-clinical through Post-marketing: 1Pre-clinical / Early Clinical: 1Commercial / Generic Development: 1Phase 1/Preclinical: 1Clinical Stage: 1Pre-clinical / CTA Cleared: 1Device Development: 1Phase 1/2 (not specified): 1Varies by Sponsor Protocol: 1Launch/Commercialization: 1Phase 4: 1Pivotal: 1NDA Filed: 1Pre-clinical/Validation: 1Research/Development: 1Commercial (LDT): 1Proof-of-Concept: 1Registrational: 1development: 1Phase III / Marketed: 1Marketed / Phase 4: 1Marketed / Phase 2/3: 1Filed: 1Phase 1-3: 1Various: 1Research to Phase 3: 1Registration: 1Late-Stage (Phase 3): 1Discovery / Preclinical / Early Clinical: 1Preclinical/Phase I: 1Discovery/Preclinical: 1Preclinical/Discovery: 1Phase 1a/b: 1Phase 1/2 / Pivotal Path: 1

Drug	Company	Indication	Phase	Status
GS1191	Gritgen Therapeutics	Hemophilia A	Phase 1	Active
lomonitinib	Lomond Therapeutics	Acute Myeloid Leukemia (AML)	IND-Enabling	Active
lonitoclax	Lomond Therapeutics	Chronic Lymphocytic Leukemia (CLL)	Phase 1	Active
Menin Inhibitor	Lomond Therapeutics	Acute Myeloid Leukemia (AML)	Discovery	Active
Stem Cell Therapy for Blood Diseases	GIOSTAR	Sickle Cell Anemia, Leukemia, Lymphoma, Thalassemia	Not Disclosed	Active
Stem Cell Therapy for Type 1 Diabetes	GIOSTAR	Diabetes (Type 1)	Under Development	Active
Stem Cell Therapy for Neurodegenerative Diseases	GIOSTAR	Alzheimer’s, Parkinson’s, ALS, Multiple Sclerosis	Under Development	Active
Stem Cell Therapy for Autoimmune Diseases	GIOSTAR	Lupus, Crohn's, Vasculitis, Scleroderma	Under Development	Active
PYRUKYND (mitapivat)	Agios Pharmaceuticals	Pyruvate kinase (PK) deficiency — adults	Approved	Commercial — FDA approved
AG-946	Agios Pharmaceuticals	Hemolytic anemias and other indications	Phase 2	Active
Multiple undisclosed preclinical programs	Agios Pharmaceuticals	Undisclosed rare diseases	Preclinical	Active discovery
IDHIFA (enasidenib) — DIVESTED	Agios Pharmaceuticals	Relapsed/refractory AML with IDH2 mutation	Approved	Divested to Servier; royalties monetized to Royalty Pharma
TIBSOVO (ivosidenib) — DIVESTED	Agios Pharmaceuticals	Relapsed/refractory AML with IDH1 mutation	Approved	Divested to Servier
MaaT013	MaaT Pharma	Acute Graft-versus-Host Disease (aGvHD)	Phase 3	Active (Pivotal)
MaaT033	MaaT Pharma	Supportive care in Hemato-Oncology	Phase 2	Active
MaaT03X	MaaT Pharma	Solid Tumors (with ICI)	Research	Discovery
DxC 500 AU Chemistry Analyzer	Beckman Coulter Diagnostics	Core Laboratory Chemistry Testing	Launched	Commercial
DxI 9000 Access Immunoassay Analyzer	Beckman Coulter Diagnostics	High-throughput Immunoassay Testing	Launched	Commercial
Digital Hematology Solutions	Beckman Coulter Diagnostics	Hematology / CBC Analysis	Development & Expansion	Active
Neurodegenerative Disease Assays (GFAP, NfL, pTau-217)	Beckman Coulter Diagnostics	Neurology / Alzheimer's Disease Research	Assay Menu Expansion	Active
Sepsis Host-Response & AMR Solutions	Beckman Coulter Diagnostics	Sepsis Diagnosis & Management	Integrated Solution	Commercial
Etiometry Clinical Intelligence Platform	Beckman Coulter Diagnostics	Critical Care / High-Acuity Patient Management	Commercial	Distributed
Advantaged Workflows	Beckman Coulter Diagnostics	Laboratory Operational Efficiency	Solution	Commercial
Accrufer (ferric maltol)	Shield Therapeutics	Iron Deficiency Anemia (IDA) in adults	Commercial	Marketed (U.S.)
Feraccru (ferric maltol)	Shield Therapeutics	Iron Deficiency Anemia (IDA) in adults	Commercial	Marketed (EU/UK)
Ferric Maltol	Shield Therapeutics	IDA in patients with Inflammatory Bowel Disease (IBD)	Phase 3	sNDA Submitted
Dupixent (dupilumab)	Regeneron	Chronic Obstructive Pulmonary Disease (COPD)	Phase 3	Active
Odronextamab	Regeneron	Relapsed/Refractory Follicular Lymphoma & DLBCL	Phase 3	Active (BLA under review)
Pozelimab	Regeneron	Complement 3 Glomerulopathy (C3G)	Phase 3	Active
Garetosmab	Regeneron	Fibrodysplasia Ossificans Progressiva (FOP)	Phase 3	Active
Linvoseltamab	Regeneron	Relapsed/Refractory Multiple Myeloma	Phase 3	Active
Fianlimab + Cemiplimab	Regeneron	Advanced Melanoma (1L adjuvant)	Phase 3	Active
REGN1908-1909 (Fel d 1 mAb)	Regeneron	Cat Allergy	Phase 3	Active
VEGF C-D	Regeneron	Neovascular Age-Related Macular Degeneration (nAMD)	Phase 2/3	Active
Narsoplimab	Omeros	HSCT-TMA	BLA Submitted	Active
OMS906	Omeros	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 2	Active
OMIDRIA	Omeros	Cataract Surgery	Marketed	Commercial
Apitegromab (SRK-015)	Scholar Rock	Spinal Muscular Atrophy (Types 2 & 3)	Phase 3	Active
SRK-181	Scholar Rock	Solid Tumors (Immuno-Oncology)	Phase 1	Active
SRK-439	Scholar Rock	Obesity / Muscle Wasting	Preclinical	Active
CellaVision Software Updates	CellaVision	Digital Cell Morphology for Peripheral Blood	Commercial	Active
Bone Marrow Aspirate Application	CellaVision	Digital Morphology for Bone Marrow Aspirates	Limited Launch	Launched in EMEA (Mar 2026)
AI & Deep Learning Integration	CellaVision	Enhanced Pre-classification & Decision Support	R&D / Integration	Active Development
Reagent Portfolio Expansion	CellaVision	Hematology Staining & Slide Preparation	Commercial	Active (Capacity Expanding)
INB-400	IN8bio	Newly Diagnosed Glioblastoma (GBM)	Phase 2	Active, enrolling
INB-200	IN8bio	Newly Diagnosed Glioblastoma (GBM)	Phase 1	Nearing completion
INB-100	IN8bio	Leukemia (post-Hematopoietic Stem Cell Transplant)	Phase 1	Active, dose escalation
INB-300 / INB-330	IN8bio	Acute Myeloid Leukemia (AML) & other cancers	Preclinical	Discovery/Preclinical
INB-500	IN8bio	Undisclosed Cancers	Preclinical	Discovery/Preclinical
NexCAR19 (talicabtagene autoleucel, Tali‑cel™)	ImmunoACT	CD19‑positive B‑cell acute lymphoblastic leukemia and large B‑cell lymphoma	Commercial	Active